Johnson & Johnson Stays Strong Amid Pharma Challenges

# Johnson & Johnson Stock Surges Near 52-Week High Following Strong Quarterly Results and FDA Priority Review Discover how Johnson & Johnson (JNJ) shares approach their 52-week high of $170, trading around $163 despite lower-than-average volume. This episode breaks down JNJ's impressive quarterly performance, with EPS of $2.77 and revenue reaching nearly $24 billion, exceeding analyst expectations across both Innovative Medicine and Medical Technology divisions. We explore the recent wave of analyst upgrades, including Royal Bank of Canada's bullish $185 target price and "outperform" rating, alongside similar positive assessments from Goldman Sachs and UBS. Learn about the FDA's priority review for JNJ's experimental bladder cancer therapy and what this means for their oncology portfolio expansion. While the company has updated guidance for higher full-year revenue and profit, we also examine potential challenges including patent expirations and pipeline visibility concerns. With low short interest and a consensus "moderate buy" rating, find out why analysts remain optimistic with 12-month price targets between $170-$175, and what this means for investors considering JNJ stock. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.